JG
FPRX

Joel Greenblatt’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Joel Greenblatt’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-11,150
Closed -$559K – 1141
2016
Q4 		$559K Sell
11,150
-2,271
-17% -$119K 0.01% 709
2016
Q3 		$704K Sell
13,421
-228,054
-94% -$10.9M 0.01% 660
2016
Q2 		$9.98M Buy
241,475
+128,508
+114% +$5.59M 0.12% 278
2016
Q1 		$4.59M Buy
+112,967
New +$3.88M 0.05% 450

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Joel Greenblatt's FPRX Position: Q1 2017 in Review

Joel Greenblatt sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2017, closing a stake of 11,150 shares — an estimated $559K sold.

Joel Greenblatt first reported a position in FPRX in Q1 2016 and held it in 4 quarters. The position peaked at $9.98M in Q2 2016. 157 funds tracked by Wall St. Rank hold FPRX as of Q1 2017.

  • Joel Greenblatt reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Joel Greenblatt sold 11,150 Five Prime Therapeutics, Inc. shares in Q1 2017, an estimated $559K.
  • Joel Greenblatt first reported a position in Five Prime Therapeutics, Inc. in Q1 2016 and held it in 4 quarters.
  • Joel Greenblatt's Five Prime Therapeutics, Inc. position peaked at $9.98M in Q2 2016.
  • 157 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2017.

Based on Gotham Asset Management's 13F filing for Q1 2017, filed 15 May 2017.